Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Treatment with Radiprodil did not show clinically meaningful reductions in mean daily pain scores, the primary endpoint, compared to placebo for any of the dosages studied, according to a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial by Forest Laboratories and Gedeon Richter.
Subscribe to our email newsletter
Forest Labs and Gedeon Richter have evaluated the investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, Radiprodil (RGH-896) in the clinical trial for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).
Radiprodil was discovered by Gedeon Richter and is currently being co-developed with Forest Laboratories as a candidate for the treatment of chronic neuropathic pain conditions, including neuropathic pain caused by diabetes mellitus.
Forest Laboratories has licensed US and Canadian rights for Radiprodil from Gedeon Richter.
Forest Labs and Gedeon Richter said that they would review the complete study database over the coming weeks to determine the appropriate next steps regarding the development of radiprodil.